MAUDE Adverse Event Report: SIEMENS HEALTHCARE DIAGNOSTICS, INC. ADVIA CENTAUR XP PROSTATE-SPECIFIC ANTIGEN (PSA); PROSTATE-SPECIFIC ANTIGEN IMMUNOASSAY

Model Number N/A

Device Problem Low Test Results (2458)

Patient Problem No Clinical Signs, Symptoms or Conditions (4582)

Event Date 02/02/2021

Event Type  malfunction  

Event Description

The customer obtained a low advia centaur xp prostate-specific antigen (psa) result for a patient sample on (b)(6) 2021 that was considered discordant when compared to the elevated result from an alternate method from (b)(6) 2021.The patient was tested again in (b)(6) 2021 on the atellica im analyzer for psa.The initial result was similar to the advia centaur psa result (lower than the alternate method result).The customer received a complaint from the patient.The same patient sample was repeated on a second atellica im on (b)(6) 2021 and the result was similar.The discordant result from the atellica im was reported to the physician and questioned.There are no known reports of patient intervention or adverse health consequences due to the discordant psa results.

Manufacturer Narrative

An outside of the united states (ous) customer contacted the siemens customer care center to report discordant low advia centaur xp prostate-specific antigen (psa) results when compared to the elevated result from an alternate method.The customer has performed an internal investigation.The customer reviewed the calibration, quality control data, and instrument status for dates (b)(6) 2021 and (b)(6) 2021 and no issues were observed.The customer has also reviewed other random psa samples.There were no changes in psa trends and the customer has not received any other queries.On (b)(4) 2021, the customer sent 5 recent random psa samples to other facilities with different platforms for concordance testing and no discordant results were observed.The ifu states in the interpretation of results section: "results of this assay should always be interpreted in conjunction with the patient's medical history, clinical presentation, and other findings." the ifu states in the limitations section: "do not interpret levels of psa as absolute evidence of the presence or the absence of malignant disease.Before treatment, patients with confirmed prostate carcinoma frequently have levels of psa within the range observed in healthy individuals.Elevated levels of psa can be observed in patients with nonmalignant diseases.Measurements of psa should always be used in conjunction with other diagnostic procedures, including information from the patient's clinical evaluation.The concentration of total psa in a given specimen determined with assays from different manufacturers can vary due to differences in assay methods, calibration, and reagent specificity.Total psa determined with different manufacturers' assays will vary depending on the method of standardization and antibody specificity." siemens healthcare diagnostics is investigating.Mdr 1219913-2022-00014 and mdr 1219913-2022-00015 were filed for the same event.

Manufacturer Narrative

Siemens filed the initial mdr 1219913-2022-00016 on january 20, 2022.January 20, 2022.Additional information: an outside of the united states (ous) customer contacted the siemens customer care center to report discordant low advia centaur xp prostate-specific antigen (psa) results when compared to the elevated result from an alternate method.The last name for the contact (chng) was provided.Section e1 was updated with the information.The catalog # 10310293 and lot number (308) used for the psa run from (b)(6) 2021 were provided.Sections d4 and h4 were updated with the information.The customer would like to send a redraw sample from the patient to siemens for further interference study.Siemens healthcare diagnostics has requested information from the customer for investigation and evaluation of the issue.Mdr 1219913-2022-00014 supplemental report 1, mdr 1219913-2022-00015 supplemental report 1, and mdr 1219913-2022-00016 supplemental report 1 were filed for the same event.

Manufacturer Narrative

Siemens filed the initial mdr 1219913-2022-00016 on january 20, 2022.Siemens filed the mdr 1219913-2022-00016 supplemental report 1 on february 14, 2022.March 02, 2022 additional information: an outside of the united states (ous) customer contacted the siemens customer care center to report discordant low advia centaur xp prostate-specific antigen (psa) results when compared to the elevated result from an alternate method.The customer did not send a redraw sample from the patient to siemens for further interference study or the requested information for further evaluation.The customer had not provided any updates or responded to requests.Based on the available information, another sample from the same patient was tested on two atellica im analyzers, and the results matched the psa low value on the advia centaur xp.The studies performed by the customer with the atellica im and the alternate method do not indicate a lot specific or system specific issue but could be attributed to the differences in the two methods, the atellica im versus the alternate method, and a patient specific issue.Per advia centaur xp psa ifu 10994905_en rev.Aa, 2020-04 warning statement: "the concentration of total psa in a given specimen, as determined by assays from different manufacturers, can vary due to differences in assay methods and reagent specificity.The results reported by the laboratory to the physician must include the identity of the assay for total psa used.Values obtained with different assay methods cannot be used interchangeably.If, in the course of monitoring a patient, the assay method used for determining serial levels of total psa is changed, the laboratory must perform additional testing to confirm baseline values." no further evaluation of the device is required.In section h6, investigation findings, and investigation conclusion codes were updated based on the investigation results.Mdr 1219913-2022-00014 supplemental report 2, mdr 1219913-2022-00015 supplemental report 2, and mdr 1219913-2022-00016 supplemental report 2 were filed for the same event.

• Brand Name: ADVIA CENTAUR XP PROSTATE-SPECIFIC ANTIGEN (PSA)
• Type of Device: PROSTATE-SPECIFIC ANTIGEN IMMUNOASSAY
• Manufacturer (Section D): SIEMENS HEALTHCARE DIAGNOSTICS, INC.; 511 benedict avemue; tarrytown NY 10591 5097
• Manufacturer (Section G): SIEMENS HEALTHCARE DIAGNOSTICS, INC.; 333 coney street; e. walpole MA 02032
• Manufacturer Contact: eiman sulieman ; 333 coney street; e. walpole, MA 02032 ; 7372808688
• MDR Report Key: 13306493
• MDR Text Key: 294403603
• Report Number: 1219913-2022-00016
• Device Sequence Number: 1
• Product Code: MTG
• Combination Product (y/n): N
• Reporter Country Code: SN
• PMA/PMN Number: P950021-S002
• Number of Events Reported: 1
• Summary Report (Y/N): N
• Report Source: Manufacturer
• Source Type: Foreign,Health Professional,User Facility
• Reporter Occupation: Other Health Care Professional
• Type of Report: Initial,Followup,Followup
• Report Date: 03/24/2022

1 Device was Involved in the Event

1 Patient was Involved in the Event

• Is this an Adverse Event Report?: No
• Is this a Product Problem Report?: Yes
• Device Operator: Health Professional
• Device Expiration Date: 07/23/2021
• Device Model Number: N/A
• Device Catalogue Number: 10310293
• Device Lot Number: 308
• Was Device Available for Evaluation?: No
• Is the Reporter a Health Professional?: Yes
• Initial Date Manufacturer Received: 12/28/2021
• Initial Date FDA Received: 01/20/2022
• Supplement Dates Manufacturer Received: 03/02/2022; 03/02/2022
• Supplement Dates FDA Received: 02/14/2022; 03/24/2022
• Was Device Evaluated by Manufacturer?: Device Not Returned to Manufacturer
• Date Device Manufactured: 07/23/2020
• Is the Device Single Use?: No
• Is This a Reprocessed and Reused Single-Use Device?: No
• Type of Device Usage: Initial
• Patient Sequence Number: 1
• Patient Age: 68 YR
• Patient Sex: Male